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Abstract
Purpose—To determine the impact of patient age, comorbidity, and physician factors on
treatment recommendations for locally-advanced, unresectable non-small cell lung cancer
(NSCLC).
Methods and Materials—We surveyed radiation oncologists regarding their recommendations
for treatment (chemoradiation, radiation alone, chemotherapy alone, or no therapy) for
hypothetical patients with stage IIIB NSCLC who varied by age (55 vs. 80 years) and comorbid
illness (none, moderate, or severe chronic obstructive pulmonary disease [COPD]). Multinomial
logistic regression was used to assess the impact of physician and practice characteristics on
radiation oncologists’ treatment recommendations for 3 scenarios with the least agreement.
Results—Of 214 radiation oncologists, nearly all (99%) recommended chemoradiation for a
healthy 55-year-old. However, there was substantial variability in recommendations for a 55-year-
old with severe COPD, an 80-year-old with moderate COPD, and an 80-year-old with severe
COPD. Physicians seeing a lower volume of lung cancer patients were statistically less likely to
recommend radiotherapy for younger or older patients with severe COPD (both p <0.05) but the
impact was modest.
Conclusions—Nearly all radiation oncologists report following evidence-based
recommendations of chemoradiation for young, otherwise healthy patients with locally advanced,
unresectable NSCLC; but there is substantial variability in treatment recommendations for older or
sicker patients, probably related to the lack of clinical trial data for such patients. The physician
and practice characteristics we examined only weakly impacted treatment recommendations.
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Additional clinical trial data are needed to guide recommendations for treatment of elderly patients
and patients with poor pulmonary function in order to optimize their management.
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INTRODUCTION
Treatment options for locally advanced, non-metastatic non-small cell lung cancer (NSCLC)
include combined modality therapy with a combination of chemotherapy and radiation
therapy (CRT), radiation therapy alone (RT), chemotherapy alone, or best supportive care.
The latter two options are purely palliative, while treatment with radiation therapy (with or
without chemotherapy) may be curative in some patients. Randomized trials have shown
that CRT is superior to RT for stage III non-small cell lung cancer, with the addition of
chemotherapy producing an absolute improvement in 2-year overall survival of
approximately 10%.1–3 As a result, recently published practice guidelines consistently
recommend CRT for unresectable NSCLC.4–7
However, not all patients are able to tolerate combined therapy, and the randomized trials
establishing the superiority of CRT over other approaches largely excluded patients with
significant comorbidity and included relatively few patients over age 70. Although
retrospective analyses demonstrate greater toxicity with combined modality therapy in older
patients compared with younger patients treated on the same protocol,8,9 these same studies
found no difference in survival for older versus younger patients. Studies in a number of
diseases have suggested that, at least for properly selected patients, aggressive therapy can
be tolerated in older patients, so that age alone should not be a criterion for denying therapy.
In addition, the parameters to define which patients have pulmonary function that would
preclude their treatment with aggressive combined modality therapy, and that might
correlate with patient age, is not well defined. Thus, it is unclear to what extent older and/or
sicker patients will benefit from CRT. Prior observational studies demonstrate that older
patients and those with more comorbidities are less often treated with chemotherapy in
addition to radiation for lung cancer,10,11 and such differences may result from uncertainty
about their likely benefit.
The data guiding treatment for individuals with significant comorbidities is even more
limited. Because of the association between smoking and lung cancer, patients with NSCLC
frequently have additional comorbidities, including some degree of chronic obstructive
pulmonary disease (COPD). The risk of radiation pneumonitis is often dose-limiting in
treating patients with locally advanced disease, and the addition of chemotherapy may
increase the risk of pulmonary toxicity after radiation.12,13 Patients with poor lung function
at baseline are less likely to tolerate treatment-associated decreases in pulmonary function;
moreover, pre-existing COPD increases the risk of radiation pneumonitis.14 Thus, less
aggressive therapy may be appropriate in patients with significant lung disease.
To understand better the influence of patient age and pulmonary comorbidity on physicians’
treatment recommendations for locally advanced NSCLC, we surveyed radiation oncologists
caring for patients with lung cancer. The purpose of our study was to document the degree
of concordance in treatment recommendations for a range of clinical scenarios and thus to
identify areas in which additional clinical trial data might be most helpful in guiding future
recommendations. Furthermore, we sought to determine whether physician and practice
characteristics influenced treatment recommendations in scenarios with substantial
discordance.
Lee et al. Page 2















Data for this study were collected as part of a national study of variations and outcomes of
care for patients with lung or colorectal cancer undertaken by the Cancer Care Outcomes
Research and Surveillance (CanCORS) Consortium.15,16 CanCORS is examining care
delivered to 5,150 patients diagnosed with lung cancer during 2003–2005 living in Northern
California, Los Angeles County, North Carolina, Iowa, or Alabama, or who received care in
one of 5 large health maintenance organizations or 10 Veterans Administration Health Care
System sites. Data collection included patient interviews, medical record abstractions,
physician surveys, and surveys of informal caregivers. The study was approved by the
human subjects committees at all participating institutions. This analysis uses only physician
survey data.
Study population
As described previously,17 we surveyed physicians named by patients as providing
important roles in their care. Of the 6871 physicians whose contact information was verified,
4188 (61%) responded. Respondents did not differ by sex (P=0.97). Radiation oncologists
vs. other physicians responded more frequently (69.8% vs. 60.7%, P=0. 005). We restricted
the sample for this analysis to the 217 physicians who identified themselves as radiation
oncologists and who cared for at least one patient with lung cancer in the past year. Further
details are included in the appendix. Data collection was closed and the dataset (version
1.6.1) finalized in March 2007.
Survey Instrument
To understand the influence of patient age (55 vs. 80 years) and level of pulmonary
comorbidity (none, moderate, severe) on radiation oncologists’ treatment recommendations
for locally advanced, unresectable NSCLC, each physician responded to the following
scenario: What treatments would you recommend for the following asymptomatic patients
with stage IIIB non-small cell lung cancer: a 55-year old man with … (1) a remote smoking
history, no dyspnea, and no other medical problems (FEV1>2.4L; >80% predicted), (2)
moderate COPD with dyspnea walking 2 blocks (FEV1=1.5L; 50% predicted), (3) severe
COPD with dyspnea on dressing (FEV1=0.75L; 25% predicted). Physicians selected one of
four choices with 1=both chemotherapy and radiation therapy, 2=radiotherapy only,
3=chemotherapy only, 4=neither chemotherapy nor radiotherapy. The scenario was repeated
using an 80-year old man as the patient. Physicians also provided information about
personal and practice characteristics, including age, sex, race/ethnicity, board certification,
United States medical graduate, teaching involvement, practice site, percentage of patients
in managed care, number of lung cancer patients cared for in the last month, whether their
practice is part of the Community Clinical Oncology Program (CCOP), whether they
practice at an NCI-designated cancer center, attendance at tumor board meetings, whether
they enroll patients in clinical trials, and base clinical income, and financial incentives for
providing radiation therapy (whether their income increases as a result of more computed
tomography based treatment planning, using greater number of fractions, or using intensity-
modulated radiation). We also documented study site for each physician. Variables were
categorized as in Table 1.
Statistical analysis
Item non-response was <2–3% for most variables. We excluded 3 physicians who did not
respond to 4 or more of the items on chemotherapy recommendations. The final sample
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included 214 physicians. We used multiple imputation to impute missing data for remaining
items.18,19
We described physicians’ treatment recommendations and then used multinomial logistic
regression models to estimate the independent effect of physician and practice
characteristics associated with treatment recommendations for the three scenarios with the
most variability: the 55 year-old with severe COPD, the 80 year-old with moderate COPD,
and the 80 year-old with severe COPD. A separate regression was performed for each of the
3 scenarios. Independent variables included all physician variables with P<.20 on bivariate
testing for at least one of the three scenarios, including physician age, number of lung-
cancer patients treated per month, study site, frequency of tumor board participation,
practice site, board certification, practice at an NCI cancer center, and practice part of a
CCOP. We calculated adjusted rates of the outcomes of interest for our patient population
using a standardized regression approach.20 All tests of statistical significance were two-
sided. We limited multivariable analyses to these 3 scenarios because there was very little
variability in responses to be explained by physician and practice characteristics in the other
3 scenarios.
RESULTS
The mean (SD) age of the radiation oncologist cohort was 50.3 (10.4). Most (81%) were
male, and less than half (36%) were engaged in teaching. Respondents had seen an average
of 10.0 (SD=12.5) lung cancer patients in the previous month (median=6). Other
characteristics of the cohort are presented in Table 1.
Radiation oncologists’ treatment recommendations varied substantially by patient age and
severity of COPD (Figure). Nearly all physicians (99%) recommended CRT for a 55-year-
old with a remote smoking history (no COPD). For the 55-year-old with moderate COPD or
the 80-year-old with a remote smoking history, a large majority (>80%) still recommended
CRT. On the other hand, less aggressive treatment was more frequently recommended for
patients with increased comorbidity and older age. For each of the three remaining scenarios
(55-year-old/severe COPD, 80-year-old/moderate COPD, and 80-year-old/severe COPD),
less than half of those surveyed recommended CRT. In particular, severe COPD appeared to
be a major deterrent to recommending radiation (either with or without chemotherapy) while
older age primarily appeared to decrease the frequency of including chemotherapy as part of
the recommendation. As a result, for the 80-year-old with severe COPD, only 3%
recommended CRT, and over 40% recommended no therapy.
For the three scenarios in which CRT was less often recommended, there was substantial
variability in recommendations, with no clear majority favoring any of the 4 treatment
options. We, therefore, analyzed whether physician or practice characteristics influenced
treatment recommendations. In the adjusted analysis (Table 2), the number of lung patients
seen per month was significantly associated with recommendations for the two scenarios
involving a patient with severe COPD, with the lowest volume radiation oncologists
recommending radiation as a component of therapy less often than higher-volume radiation
oncologists (both P<.05). Physicians in hospital-based vs. office-based practices were more
likely to include chemotherapy in their recommendations for the 80-year old patient with
moderate COPD and physicians practicing at NCI cancer centers were somewhat less likely
than other physicians to recommend CRT to an 80-year old patient with moderate COPD
and more likely to recommend no treatment; however, these findings were of borderline
statistical significance (both P=.06) and differences in recommendations were modest. None
of the remaining variables were significantly associated with treatment recommendations in
any of the three scenarios modeled.
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In this survey of geographically diverse radiation oncologists, we found that nearly all of
them would recommend CRT for a 55-year-old man with stage III NSCLC and only a
remote smoking history. However, there was less agreement regarding recommendations for
patients who were older and/or had moderate to severe COPD. In the three scenarios with
the greatest variability, the only physician variable that was significantly associated with
treatment recommendations was the volume of lung-cancer patients treated. Prospective
randomized trials comparing CRT with RT alone for unresectable, locally advanced NSCLC
have clearly demonstrated improved overall survival with the addition of chemotherapy to
radiation.1–3 As a result, treatment guidelines from a number of different expert panels
recommend CRT with curative intent for patients with unresectable NSCLC.4–7 Thus, it is
not surprising that there was essentially unanimous agreement on recommending CRT for
the young, otherwise healthy patient. Our findings confirm that a strong consensus is
achievable with high-quality, randomized data.
However, in the scenarios which are likely to be more representative of typical lung-cancer
patients, who are older and have some degree of COPD, the decreasing consensus likely
reflects the uncertainty in the literature regarding optimal treatment for patients who are not
ideal candidates for CRT. The trials establishing the superiority of CRT over RT generally
included only patients with good performance status (Zubrod 0–1) and minimal weight loss
(<5%), and the published treatment guidelines are firm in recommending CRT only for such
patients. For patients who do not meet these criteria, recommendations vary from offering
CRT to patients with borderline performance status only after careful consideration to
offering only palliative therapy for symptomatic patients with poor performance status or
greater than 10% weight loss.
Notably, treatment guidelines generally do not recommend offering less aggressive therapy
on the basis of advanced age alone. Randomized data on the importance of age are limited
since some trials excluded or included relatively few patients who were over 70 years-
old.2,21 Retrospective analyses specifically examining the benefit of adding chemotherapy in
the elderly have yielded mixed results, depending in part on the outcome of interest. For
instance, a quality-adjusted survival analysis showed that RT alone yielded the best quality-
adjusted survival in patients over 70 years-old.22 More recently, a randomized trial of
concurrent versus sequential CRT showed a similar benefit to concurrent CRT between
patients older than 70 and younger than 70.23 Based on currently available data, most
experts advocate treating “fit” (performance status 0–1) elderly patients in a fashion similar
to their younger counterparts.6,7 Consistent with this recommendation, most (85%) radiation
oncologists in our cohort reported they would treat an 80-year-old man without COPD
similarly to the 55-year-old, although 13% of physicians would recommend RT alone for
such men.
Differences in recommendations based on patient age were amplified in the setting of
moderate or severe COPD, with radiation oncologists tending to recommend less aggressive
therapy overall for older patients. This finding is consistent with findings of the Patterns of
Care Study, which showed that patients younger than 70 were more likely than those older
than 70 to receive chemotherapy in addition to radiation for stage III NSCLC.10 This
difference may reflect concern about the potential increased risk of toxicity among older
patients receiving chemotherapy in addition to radiation therapy.8,9 The question of whether
such concern is justified would ideally be addressed in a randomized trial of CRT versus RT
alone designed specifically for older patients, who were under-represented in prior trials.
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Because the Patterns of Care Study10 included only patients who received radiation as a
component of their treatment, it does not provide information on the proportion of patients
treated with either chemotherapy alone or best supportive care. Our study suggests that most
radiation oncologists would not recommend any radiation in patients with severe COPD,
regardless of age. The sharp decrease in the frequency of radiation being recommended is
likely related to concern that patients with severe COPD may not tolerate the potential
pulmonary toxicity associated with radiation. It is also consistent with the statement in the
ACCP guidelines that a patient with FEV1 <1L/s is unlikely to withstand definitive
therapy.4 However, there are no good prospective data demonstrating that an attempt at
definitive RT would indeed be detrimental in patients with severe COPD.
Potential reasons for the lack of consensus in the three most variable scenarios include a
shortage of evidence to guide therapy in non-ideal candidates for CRT or physician factors
that could lead to treatment recommendations in the absence of strong data. Among the
radiation oncologists studied, we found that variability in responses was influenced only by
the number of lung-cancer patients treated per month. Overall, however, the variability we
observed in the scenarios with “non-ideal” patients was not well-explained by physician
characteristics. Thus, our data suggest that the variability we observed for older and sicker
patients is unlikely to be significantly reduced by addressing any particular subset of
physicians.
The reluctance of “low volume” physicians in this study to offer radiation in the scenarios
involving patients with severe COPD suggests that those with less experience may be more
concerned about the reported increase risk of pulmonary toxicity in those with pre-existing
lung disease.14 Prior studies have shown that higher patient volume may improve outcomes
for cancer patients, particularly for patients undergoing surgery.24 Radiation oncologists
who treat fewer patients with lung cancer may be less comfortable managing radiation-
induced lung toxicity in part because of their own lack of experience and in part because
their colleagues (within the same institution but in other specialties) may also have less
experience managing the side effects of lung radiation. It has been reported that increased
volume at the institutional level is associated with improved survival for locally advanced
lung cancer.25 Although the recommendations of the lower-volume physicians in this study
may be appropriate, our data suggest that, in general, the impact of patient volume on
outcomes may be related not only to technical factors but also to differences in the overall
approach to therapy.
A limitation of this study is our use of clinical vignettes and our reliance on physicians’ self-
reports to assess care. Although others have demonstrated that vignettes can provide a valid
measure of clinical care,26 physicians might overestimate their propensity to provide
guideline-concordant care. Moreover, the lack of detail in each scenario may have
contributed to the variability in physician response. Furthermore, the vignette patients
represented only 2 ages and 3 levels of severity of a single medical condition, and responses
may have been different had we used an illness other than COPD. Also, although the
vignettes describe the patients’ symptoms, there was no specific information about
performance status or degree of weight loss, which some recommendations suggest should
be used to guide care.
In addition, the response options were limited to CRT, RT alone, chemotherapy alone, or
neither and did not distinguish between sequential and concurrent CRT, or between
definitive and palliative RT; nor did they allow physicians to provide reasons for their
recommendations. Recent data show concurrent CRT offers superior cancer control in
comparison to sequential therapy but is also more toxic.27,28 In practice, patients who are
suboptimal candidates for concurrent CRT may be offered sequential therapy, so it is likely
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that increasing the number of possible responses would have increased the variability we
observed, particularly in the 55-year-old with moderate COPD or the 80-year-old with no
COPD. Similarly, it is possible that those who recommended RT alone would have been
divided with regard to whether the RT was given with curative or palliative intent.
Finally, only radiation oncologists were questioned about recommendations for treatment of
patients with unresectable lung cancer; medical oncologists may have had differing views.
Moreover, our survey is subject to non-response bias and patients’ reports may not have
identified all radiation oncologists in an area, so we cannot be certain that the radiation
oncologists in our sample were representative of those caring for cancer patients in the
regions studied or nationally. However, the correlation between our results and those of the
Patterns of Care Study suggest that our data do provide a reasonable sample of physicians in
the United States.
In conclusion, nearly all radiation oncologists recommended CRT for stage III NSCLC for a
young, otherwise healthy patient, demonstrating that radiation oncologists are willing to
follow strong, randomized data. However, they differ widely on recommendations for
patients who are older or have significant lung disease, suggesting that radiation oncologists
are less willing to extrapolate the results of randomized trials to patients who were not
actually included on the trials. Thus, additional clinical trial data are needed to guide
recommendations for older patients and those with moderate to severe COPD, populations
that have been largely excluded from previous trials. Although such trials are challenging to
conduct given heterogeneity in patients’ baseline pulmonary function, tumor characteristics,
and other comorbidities, given that these patients, in fact, comprise the majority of “real
world” patients, such trials would likely optimize care for these patients by decreasing
variations due to poorly substantiated, individual or regional beliefs about the likely benefits
and risks of available treatments in different types of patients.
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Appendix. CanCORS Physician Survey Development and Administration
Survey Development
The CanCORS physician survey was designed to collect information that can only be
obtained reliably from physicians, including physicians’ beliefs about treatments,
physicians’ style of practice, physicians’ practice characteristics and financial arrangements,
and physicians’ demographics. When possible, items were taken (or adapted) from
previously developed instruments. When items were not available from prior surveys, new
questions were developed.
Five versions of the survey instrument were developed, each tailored to the type of physician
who would be responding based on the role reported by the patient: (1) surgeons, (2)
chemotherapy providers, (3) radiation therapy providers, (4) non-cancer specialists caring
for colorectal cancer patients, and (5) non-cancer specialists caring for lung cancer patients.
Where possible, questions on each version were identical. Some versions had additional
questions specific to that discipline (for example, surgeons had questions specifically about
volume of surgical operations).
The survey instruments underwent 2 rounds of cognitive testing by survey development staff
at Westat, Inc., each followed by revisions to the instrument. In the first round of cognitive
testing, 12 physicians from the Washington, D.C. metropolitan area provided feedback about
specific questions. After revisions to the questionnaire, 16 physicians from around the
country completed the self-administered survey and then were interviewed by research staff.
The survey instrument was revised to improve clarity and decrease the length. Questions
were dropped if they were difficult to answer, were not likely to provide data with variation,
or were of lower priority relative to the CanCORS synthesis document and analytic work
plans.
Cohort
The target population of the provider survey was physicians who had important roles in the
care of patient participants in CanCORS. The CanCORS patient cohort is a population-based
cohort of individuals diagnosed with lung or colorectal cancer at one of the participating
sites (8 counties in Northern California, Los Angeles County, the state of Iowa, the state of
Alabama, 22 counties in central/eastern North Carolina, 5 integrated delivery systems, and
10 Veterans Administration Medical Centers). Table A1 summarizes the cohorts of newly
diagnosed patients who were ascertained and enrolled. CanCORS participants are similar to
patients diagnosed with cancer in the U.S. as a whole (Catalano et al, unpublished
manuscript.
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In the patient survey, we identified physicians who played important roles in each patient’s
care, including physicians who discussed and/or provided surgery, chemotherapy, or
radiation therapy, providers important in referring patients to surgeons (lung cancer patients
only), chemotherapy providers, or radiation providers, and providers most likely to know if
the patient has a symptom. If a patient did not discuss surgery, chemotherapy, or radiation
therapy with any providers, then we surveyed the doctor that they reported was most
important in treatment decisions.
At one site (Veterans Administration hospitals), the patient survey was not used to identify
physicians. Rather, researchers identified all physicians with whom patients had interactions
based on review of the inpatient and outpatient medical records. Because many patients had
interactions with residents and fellows that were transiently at the VA hospitals, and because
these trainees were working with attending physicians, only attending physicians are
included in analyses.
Each site verified the names and contact information of physicians. Attempts were made to
verify physicians’ specialties to assure that the appropriate survey instrument be mailed to
them. For example, if the doctor with whom a patient discussed surgery was actually their
primary care doctor, then the physician would receive a survey instrument tailored to a non-
cancer specialist rather than one tailored to a surgeon.
Physicians who were mental health providers were ineligible for participation, consistent
with the decision in CanCORS to not collect information about patients’ mental health. If
physicians had moved or retired, attempts were still made to contact those physicians,
although such attempts were typically unsuccessful.
Survey Administration Procedures
Physicians were mailed a self administered questionnaire. The questionnaire was
accompanied by a cover letter printed on letterhead from the primary data collection site and
was co-signed by the Director of the National Cancer Institute and the Medical Director of
the American Cancer Society. Each packet also included one or more letters of endorsement
matched to the recipient’s specialty (including the American College of Surgeons, American
Society of Clinical Oncologists, American Society of Therapeutic Radiology and Oncology,
American Thoracic Society, American College of Chest Physicians, American
Gastroenterological Association, American College of Physicians, and American Academy
of Family Physicians).
Surveys were mailed by priority mail with a stamped, pre-addressed return envelope.
Physicians were also given the option of responding to the survey via a secure website, after
logging in with a username and password. Each survey was coded with a unique identifier to
be used to link providers with patients and for follow-up of nonresponders. Three weeks
after the initial mailing, another copy of the survey and cover letter was sent by first class
mail to all nonresponders. Approximately two weeks later, a research assistant placed phone
calls to the offices of nonresponding physicians to verify that the survey had been received,
encourage physicians to complete and return it, and offer to mail or fax a replacement
questionnaire. Up to 10 attempts were made to reach each nonresponding physician. After
another 6–8 weeks, a third mailing of the survey and cover letter was sent to non-responding
physicians.
For each survey, the initial mailing included an incentive. At most sites, this incentive was
in the form of a $20 check. At two sites, the incentive was a non-monetary gift card with a
$20 value. At the one site, this incentive was a $50 check incentive, due to the concern that
$20 would not be sufficient compensation to positively influence survey response in this
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area. At a final site, a randomized trial of a $50 check or a $20 check incentive was
conducted for the first 578 physicians; because of a significantly higher response rate, the
remaining physicians received a $50 check (Keating et al, Med Care 2008, in press).
One Primary Data Collection and Research Center (PDCR) site made the initial contact with
physicians by email. In this case, the body of the email included a brief message that
mentioned the survey, described the attachments (cover letter and endorsement letter),
included the URL to take the survey via the internet, and noted that they will be receiving a
mailing within the week that included a $20 check and a paper copy of the instrument.
The survey administration procedures were tested at each site using a run-in period during
the summer of 2004 where each site mailed the first 30 surveys. The remaining surveys were
administered on a rolling basis during January 2005 through March 2007, although only 2%
of the surveys were mailed after May 2006.
Data Entry
For web-based survey responses (13% of responses), data were entered directly into the
Statistical Coordinating Center database from the web survey instrument. For paper survey
responses, data were double entered by staff at each PDCR site into a web version of the
instrument specifically designed for data entry.
Response Rates
We calculated absolute response rates and participation rates. The absolute response rate
was defined as the response rate among all physicians who are believed to have cared for
CanCORS patients. This includes a small number of physicians who are deceased or no
longer in practice and physicians named by patients but whom sites were not able to identify
valid contact information. The absolute response rate for the survey was 53.2%. The
participation rate was defined as the response rate among physicians who cared for
CanCORS patients, are not deceased or retired, and for whom sites were able to identify
valid contact information. The overall participation rate was 61.0%. Absolute response rates
and participation rates by site and physician characteristics are included in Table A2.
Physicians in Northern California, Iowa, Los Angeles County, and those practicing in the
Cancer Research Network managed care organizations were most likely to respond.
Response rates did not differ by physician sex, but physicians who graduated from medical
school in 1983–1989 were less likely than others to respond. Physicians providing radiation
therapy were most likely to respond, and non-cancer specialists caring for colorectal cancer
patients were least likely to respond.
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Unadjusted frequencies of treatment recommendations for each clinical scenario.
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Table A1




All ascertained cases* 14327 13304 27631
Sampled cases 11659 10250 21909
Physician consent to enroll 11329 10042 21371
Successful contact of household 8352 7848 16200
Eligible after contact 7914 7309 15223
Enrolled 5150 4914 10064
Absolute response rate
  (response rate among patients
  approved by physician for contact
  and not known to be ineligible)
47.3% 51.7% 49.3%




Cases were ascertained by rapid case ascertainment.
Data prepared December 13, 2007.
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Table A2









Primary data collection site <.001 <.001
  Northern California 63.4 66.4
  Los Angeles County 57.2 61.6
  Alabama 44.4 58.2
  Iowa 59.4 64.3
  North Carolina 47.6 53.8
  Cancer Research Network 55.4 64.9
  Veterans Administration 38.8 53.7
Sex‡ .32 .97
  Male 59.6 63.9
  Female 58.1 63.8
Year graduated from medical
school‡ .008 .005
  Before 1976 62.7 65.8
  1976–1982 60.3 62.5
  1983–1989 57.1 60.5
  1990 or later 59.9 65.3
Survey version .006 .001
  Surgeon 54.3 62.5
  Chemotherapy physician 50.8 61.2
  Radiation physician 57.3 69.8
  Non-cancer specialist caring
   for colorectal cancer patient
50.9 57.8
  Non-cancer specialist caring
   for lung cancer patient
55.0 61.3
*
The absolute response rate was defined as the response rate among all physicians who are believed to have cared for CanCORS patients. This
includes a small number of physicians who are deceased or no longer in practice and physicians named by patients but for who sites were not able
to identify valid contact information. The participation rate was defined as the response rate among physicians who cared for CanCORS patients,
are not deceased or retired, and for whom sites were able to identify valid contact information.
†
Using the Pearson chi square test.
‡
There were 972 nonresponders with missing information on sex and 916 nonresponders with missing information on year graduated from medical
school, and these individuals not included. Thus, the analyses assume that the distribution of those with missing information is similar to those with
complete information.
Data based on Physician Survey Data Version 1.6.1, prepared March 2007.
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